Literature DB >> 20052708

HER2- and EGFR-specific affiprobes: novel recombinant optical probes for cell imaging.

Ilya Lyakhov1, Rafal Zielinski, Monika Kuban, Gabriela Kramer-Marek, Robert Fisher, Oleg Chertov, Lakshman Bindu, Jacek Capala.   

Abstract

The human epidermal growth factor receptors, EGFR and HER2, are members of the EGFR family of cell-surface receptors/tyrosine kinases. EGFR- and HER2-positive cancers represent a more aggressive disease with greater likelihood of recurrence, poorer prognosis, and decreased survival rate, compared to EGFR- or HER2-negative cancers. The details of HER2 proto-oncogenic functions are not deeply understood, partially because of a restricted availability of tools for EGFR and HER2 detection (A. Sorkin and L. K. Goh, Exp. Cell Res. 2009, 315, 683-696). We have created photostable and relatively simple-to-produce imaging probes for in vitro staining of EGFR and HER2. These new reagents, called affiprobes, consist of a targeting moiety, a HER2- or EGFR-specific Affibody molecule, and a fluorescent moiety, mCherry (red) or EGFP (green). Our flow cytometry and confocal microscopy experiments demonstrated high specificity and signal/background ratio of affiprobes. Affiprobes are able to stain both live cells and frozen tumor xenograph sections. This type of optical probe can easily be extended for targeting other cell-surface antigens/ receptors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20052708      PMCID: PMC3092587          DOI: 10.1002/cbic.200900532

Source DB:  PubMed          Journal:  Chembiochem        ISSN: 1439-4227            Impact factor:   3.164


  34 in total

Review 1.  Creating new fluorescent probes for cell biology.

Authors:  Jin Zhang; Robert E Campbell; Alice Y Ting; Roger Y Tsien
Journal:  Nat Rev Mol Cell Biol       Date:  2002-12       Impact factor: 94.444

Review 2.  [Protein transduction by poly-arginine].

Authors:  Hideki Matsui; Kazuhito Tomizawa; Masayuki Matsushita
Journal:  Nihon Yakurigaku Zasshi       Date:  2003-06

3.  An enhanced green fluorescent protein allows sensitive detection of gene transfer in mammalian cells.

Authors:  G Zhang; V Gurtu; S R Kain
Journal:  Biochem Biophys Res Commun       Date:  1996-10-23       Impact factor: 3.575

4.  Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain.

Authors:  K Nord; E Gunneriusson; J Ringdahl; S Ståhl; M Uhlén; P A Nygren
Journal:  Nat Biotechnol       Date:  1997-08       Impact factor: 54.908

5.  111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors.

Authors:  Vladimir Tolmachev; Fredrik Y Nilsson; Charles Widström; Karl Andersson; Daniel Rosik; Lars Gedda; Anders Wennborg; Anna Orlova
Journal:  J Nucl Med       Date:  2006-05       Impact factor: 10.057

Review 6.  EGFR and cancer prognosis.

Authors:  R I Nicholson; J M Gee; M E Harper
Journal:  Eur J Cancer       Date:  2001-09       Impact factor: 9.162

Review 7.  Untangling the ErbB signalling network.

Authors:  Y Yarden; M X Sliwkowski
Journal:  Nat Rev Mol Cell Biol       Date:  2001-02       Impact factor: 94.444

8.  Effects of 131I-EGF on cultured human glioma cells.

Authors:  J Capala; M Pråhl; S Scott-Robson; J Pontén; B Westermark; J Carlsson
Journal:  J Neurooncol       Date:  1990-12       Impact factor: 4.130

Review 9.  HER2 overexpression and cancer targeting.

Authors:  S C Wang; M C Hung
Journal:  Semin Oncol       Date:  2001-10       Impact factor: 4.929

Review 10.  The HER receptor family: a rich target for therapeutic development.

Authors:  Robert D Mass
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-03-01       Impact factor: 7.038

View more
  14 in total

Review 1.  Protein-based tumor molecular imaging probes.

Authors:  Xin Lin; Jin Xie; Xiaoyuan Chen
Journal:  Amino Acids       Date:  2010-03-17       Impact factor: 3.520

2.  Sarcosine induces increase in HER2/neu expression in androgen-dependent prostate cancer cells.

Authors:  Malin Dahl; Pierre Bouchelouche; Gabriela Kramer-Marek; Jacek Capala; Jørgen Nordling; Kirsten Bouchelouche
Journal:  Mol Biol Rep       Date:  2011-07-14       Impact factor: 2.316

Review 3.  Beyond Antibodies as Binding Partners: The Role of Antibody Mimetics in Bioanalysis.

Authors:  Xiaowen Yu; Yu-Ping Yang; Emre Dikici; Sapna K Deo; Sylvia Daunert
Journal:  Annu Rev Anal Chem (Palo Alto Calif)       Date:  2017-03-24       Impact factor: 10.745

4.  Hyperthermia-triggered intracellular delivery of anticancer agent to HER2(+) cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2(+) affisomes).

Authors:  Brandon Smith; Ilya Lyakhov; Kristin Loomis; Danielle Needle; Ulrich Baxa; Amichai Yavlovich; Jacek Capala; Robert Blumenthal; Anu Puri
Journal:  J Control Release       Date:  2011-04-09       Impact factor: 9.776

5.  Design, synthesis and characterization of peptidomimetic conjugate of BODIPY targeting HER2 protein extracellular domain.

Authors:  Sashikanth Banappagari; Alecia McCall; Krystal Fontenot; M Graca H Vicente; Amit Gujar; Seetharama Satyanarayanajois
Journal:  Eur J Med Chem       Date:  2013-04-28       Impact factor: 6.514

6.  Optical imaging of ovarian cancer using HER-2 affibody conjugated nanoparticles.

Authors:  Minati Satpathy; Rafal Zielinski; Ilya Lyakhov; Lily Yang
Journal:  Methods Mol Biol       Date:  2015

7.  Immediate in vivo target-specific cancer cell death after near infrared photoimmunotherapy.

Authors:  Makoto Mitsunaga; Takahito Nakajima; Kohei Sano; Gabriela Kramer-Marek; Peter L Choyke; Hisataka Kobayashi
Journal:  BMC Cancer       Date:  2012-08-08       Impact factor: 4.430

8.  In vivo fluorescence lifetime imaging monitors binding of specific probes to cancer biomarkers.

Authors:  Yasaman Ardeshirpour; Victor Chernomordik; Rafal Zielinski; Jacek Capala; Gary Griffiths; Olga Vasalatiy; Aleksandr V Smirnov; Jay R Knutson; Ilya Lyakhov; Samuel Achilefu; Amir Gandjbakhche; Moinuddin Hassan
Journal:  PLoS One       Date:  2012-02-23       Impact factor: 3.240

9.  Affibody-DyLight conjugates for in vivo assessment of HER2 expression by near-infrared optical imaging.

Authors:  Rafal Zielinski; Moinuddin Hassan; Ilya Lyakhov; Danielle Needle; Victor Chernomordik; Alejandra Garcia-Glaessner; Yasaman Ardeshirpour; Jacek Capala; Amir Gandjbakhche
Journal:  PLoS One       Date:  2012-07-20       Impact factor: 3.240

10.  Heptameric targeting ligands against EGFR and HER2 with high stability and avidity.

Authors:  Dongwook Kim; Yitang Yan; C Alexander Valencia; Rihe Liu
Journal:  PLoS One       Date:  2012-08-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.